What is KPTI's market cap?

$1.65M, based on the Nov 4 close of $0.07.

Does Karyopharm Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of KPTI is sold short?

7.3M shares, 34.2% of float, as of Oct 15, 2026.

What sector is KPTI in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · KPTIHealthcarePharmaceuticals

Karyopharm Therapeutics Inc. (KPTI)

$0.0729−17.44%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$0.07▼ 98.71% in range

Nov 4, 2025Low $0.07 · High $10.67Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Karyopharm Therapeutics closed at $0.07 on Nov 4, down 17.44%, within 0.0% of its 52-week closing low. Volume of 40.9M shares was 5.22× its 20-day average (well above normal).

Split-adjusted performance: -88.8% over one month, -99.2% over six months, -98.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $33.43M, down 11.9% from a year earlier, with a net margin of -200.5%.

Short interest was 7.3M shares at the Oct 15 settlement, up 20.0% from the prior report (34.2% of float, 4.8 days to cover).

Market cap$1.7M22.7M shares

Revenue · quarter$33.4M−11.9% YoY

Diluted EPS$-2.32—

P/E · TTM—P/S 0.0×

Net margin-200.5%Gross 96.8%

Dividend yieldNone

52-week range0.07 – 10.67−99.3% from high

Volume40.9M5.22× 20-day avg

Volatility · 60d413.8%Annualised

Short % of float34.2%4.8 days to cover

Net cash-$184.8MCash $65.1M

Next earnings—Not scheduled

Split-adjusted performance

1W −91.2%1M −88.8%3M −96.3%6M −99.2%YTD −99.0%1Y −98.8%3Y −99.4%5Y −99.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum0

Revenue growth32

Net margin38

Value (low P/E)—

Size2

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short7.3M+20.0% vs prior

Days to cover4.8Settled Oct 15

% of float34.2%

Short vol. 10d55.3%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
KPTIKaryopharm Therapeutics	$0.0729	−17.44%	−99.2%	−11.9%	−200.5%	—	$1.7M
KAPAKairos Pharma	$0.4897	−3.03%	−87.4%	—	—	—	$1.7M	Compare
OGENOragenics	$0.3720	+0.51%	−40.0%	—	—	—	$1.7M	Compare
GNPXGenprex	$2.14	−7.36%	−89.1%	—	—	—	$1.8M	Compare
ELABPMGC Holdings	$1.92	−1.03%	−91.0%	—	−225.1%	—	$1.6M	Compare
PPCBPropanc Biopharma	$1.79	+4.68%	−92.9%	—	—	—	$1.8M	Compare
GOVXGeoVax Labs, Inc. New	$0.1680	+2.38%	−89.8%	−100.0%	—	—	$1.5M	Compare
SBFMSunshine Biopharma	$2.65	−3.28%	−98.8%	−1.6%	−16.9%	—	$2.0M	Compare
ARTLArtelo Biosciences	$2.27	−5.42%	−90.9%	—	—	—	$1.2M	Compare

News about Karyopharm Therapeutics

All news →

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTIGlobeNewswire Inc. · Aug 4, 2026▼ Negative Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 CongressGlobeNewswire Inc. · Jun 14, 2026▲ Positive

Quick answers

What does Karyopharm Therapeutics do?: Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein.
What is KPTI's market cap?: $1.65M, based on the Nov 4 close of $0.07.
Does Karyopharm Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of KPTI is sold short?: 7.3M shares, 34.2% of float, as of Oct 15, 2026.
What sector is KPTI in?: Healthcare, in the Pharmaceuticals industry.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

HQ: Newton, MA228 employeesListed Nov 6, 2013karyopharm.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology